If the Australian government were to start employing rapid testing, what are Atomo's chances of getting a piece of that pie? One thing all long term AT1 holders have learned is that the market overly weighs Atomo's COVID involvement even though the majority of its value is in the technology (although the fact that Atomo had functional antibody tests within a month of the pandemic start is a great demonstration of their product's flexibility), I am wondering if getting an Australia-related COVID test contract may cause a disproportionately large share price increase. Unfortunately, if the market opportunity opens up and is fully filled by competitors I could see the share getting dumped hard.
Does anyone have an overview of the state of the competition at the moment?
AT1 Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
